Abstract 152P
Background
Till date, intensity-modulated radiation therapy (IMRT) with concurrent chemoradiotherapy (CCRT) and CCRT with standard fractionation three-Dimensional Conformal Radiation Therapy (3D-CRT) have not been compared. In the current study, the outcomes of IMRT-based concurrent chemoradiotherapy (CCRT) and those of 3D-CRT-based CCRT were compared in patients with thoracic esophageal squamous cell carcinoma (TESCC).
Methods
We enrolled 2062 patients with TESCC who had received CCRT and categorized them into two groups based on their treatment modality: group 1 (3D-CRT-based CCRT) and group 2 (IMRT-based CCRT).
Results
The multivariate Cox regression analysis indicated that advanced stages (≥IIIA) of the American Joint Committee on Cancer and 3D-CRT were significant independent predictors of poor outcome in patients with TESCC who received definitive CCRT. Moreover, receiving IMRT-based CCRT (adjusted HR [aHR]: 0.88; 95% confidence interval [CI]: 0.78-0.98) was a significant independent prognostic factor for overall survival (P = .0223). The aHRs (95% CIs) for overall mortality at early (IA-IIB) and advanced clinical stages were 0.91 (0.67-1.25, P = .5746) and 0.88 (0.77-0.99, P = .0368), respectively, in group 2.
Conclusions
IMRT-based CCRT resulted in higher survival rates in the patients with advanced clinical stages IIIA-IIIC TESCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract
184P - Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression
Presenter: Jun Ji
Session: Poster display session
Resources:
Abstract